Healthcare Services

Kidney Cancer Diagnostics And Therapeutics Market Analysis Through 2030 Focusing On Demand Trends And Growth Drivers

June 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Size Of The Kidney Cancer Diagnostics And Therapeutics Market Progress Through 2030?

The kidney cancer diagnostics and therapeutics market has shown substantial expansion in recent years. It is anticipated to increase from $4.31 billion in 2025 to $4.6 billion in 2026, registering a compound annual growth rate (CAGR) of 6.8%. This historical growth can be linked to factors like a rising incidence of renal cell carcinoma, improvements in imaging and biopsy techniques, the widespread adoption of targeted therapies, greater understanding of early cancer diagnosis, and the establishment of more oncology treatment centers.

The kidney cancer diagnostics and therapeutics market is projected to experience substantial expansion in the coming years. It is forecast to reach $6.08 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%. Factors driving this growth during the forecast period include the increased uptake of immunotherapy regimens, higher investments in oncology research, the expanding application of genomic testing in cancer treatment, the broadening of precision medicine strategies, and enhanced access to sophisticated cancer diagnostics. Key trends anticipated during the forecast period involve a greater embrace of targeted and immunotherapy treatments, more frequent utilization of advanced imaging for early detection, a rising need for personalized kidney cancer therapies, the proliferation of biomarker-based diagnostic methods, and better synergy between diagnostics and therapeutics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11937&type=smp

What Key Growth Drivers Are Influencing The Kidney Cancer Diagnostics And Therapeutics Market?

The escalating prevalence of kidney cancer is poised to drive the expansion of the kidney cancer diagnostics and therapeutics market. This condition arises when normal kidney cells undergo abnormal, uncontrolled growth, leading to a mass known as a renal cortical tumor. Kidney cancer diagnostics and therapeutics are essential for disease management and treatment, providing numerous patient advantages such as early detection, accurate diagnosis, informed treatment selection, personalized medicine strategies, and continuous treatment monitoring. For example, in May 2024, the American Cancer Society, a US-based nonprofit cancer research and advocacy organization, estimated 81,610 new kidney cancer cases would be diagnosed in 2024, with 14,390 projected deaths. Hence, the rising incidence of kidney cancer is anticipated to propel the growth of the kidney cancer diagnostics and therapeutics market.

How Is The Kidney Cancer Diagnostics And Therapeutics Market Distributed Across Key Segments?

The kidney cancer diagnostics and therapeutics market covered in this report is segmented –

1) By Cancer Type: Clear Cell RCC, Papillary RCC, Chromophobe RCC, Urothelial Carcinoma And Transitional Cell Carcinoma

2) By Component: Drugs, Diagnostics

3) By Therapy: Targeted Therapy, Immunotherapy

4) By End-Users: Hospitals, Genomics Laboratories

Subsegments:

1) By Clear Cell RCC: Stage I, Stage II, Stage III, Stage IV

2) By Papillary RCC: Type 1, Type 2

3) By Chromophobe RCC: Localized, Advanced

4) By Urothelial Carcinoma And Transitional Cell Carcinoma: Non-Muscle Invasive, Muscle Invasive, Metastatic

Which Trends Are Expected To Shape The Kidney Cancer Diagnostics And Therapeutics Market?

Major companies within the kidney cancer diagnostics and therapeutics market are focusing on developing advanced approaches for renal cell carcinoma (RCC) to improve patient outcomes and offer innovative treatment options tailored to the specific needs of individuals diagnosed with this challenging disease. Research into renal cell carcinoma (RCC) is essential for kidney cancer diagnostics and therapeutics, as it drives the creation of innovative diagnostic methods and targeted therapies that enhance early diagnosis and individualized treatment for patients. For instance, in December 2023, Merck, a US-based pharmaceutical company, launched welireg (belzutifan), the first hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor approved for adult patients with advanced renal cell carcinoma (RCC) after prior treatments with PD-1 or PD-L1 inhibitors and VEGF-TKIs. This novel therapeutic class shows significant benefits, including improved progression-free survival and higher response rates compared to everolimus. WELIREG’s approval represents a crucial advancement in the kidney cancer diagnostics and therapeutics market, offering new hope for patients with progressing disease.

Which Companies Are Influencing The Kidney Cancer Diagnostics And Therapeutics Market?

Major companies operating in the kidney cancer diagnostics and therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co., Ltd., Ipsen S.A., Exelixis Inc., Illumina Inc., QIAGEN N.V., Myriad Genetics Inc., Guardant Health Inc., Invitae Corporation, Bio-Rad Laboratories, Inc., Laboratory Corporation of America Holdings

Access The Complete Kidney Cancer Diagnostics And Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/kidney-cancer-diagnostics-and-therapeutics-global-market-report

Which Region Has The Strongest Presence In The Kidney Cancer Diagnostics And Therapeutics Market?

North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Kidney Cancer Diagnostics And Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=11937&type=smp

Browse Through More Reports Similar to the Global Kidney Cancer Diagnostics And Therapeutics Market 2026, By The Business Research Company

Basal Cell Carcinoma Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/basal-cell-carcinoma-treatment-global-market-report

Kidney Cancer Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report

Renal Biomarkers Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795